Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
remifentanil + propofol
- Development stage
- Unknown
- Lead developer
- Norwegian University of Science and Technology
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Remifentanil + propofol is a combination sedation protocol consisting of the ultra-short-acting mu-opioid receptor agonist remifentanil and the sedative-hypnotic GABA-A receptor modulator propofol. This specific combination was investigated by the Norwegian University of Science and Technology (NTNU) in a Phase 4 randomized controlled trial (NCT00667043) for the management of sedation in patients undergoing therapeutic hypothermia following cardiac arrest. The protocol aims to provide titratable sedation and analgesia with a rapid offset to facilitate neurological assessment and extubation. Clinical findings indicated that while the combination significantly reduced the time to awakening compared to a fentanyl/midazolam regimen, it was associated with an increased requirement for vasopressor support due to hemodynamic effects.
- Other names
- remifentanil and propofol
02
Targets
GABRR (GABA-A receptor subunit rho)MOR (Mu opioid receptor)
Beyond the preview
Go deeper on remifentanil + propofol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on remifentanil + propofol.